Acute pancreatitis is caused by the activation of digestive enzymes in the pancreas and a possible treatment, therefore, is the inhibition of enzyme secretion. 
analogue, octreotide, has been investigated in several clinical studies. A meta analysis of six individual studies in which somatostatin was given for acute pancreatitis showed that somatostatin significantly reduces mortality. A trial in patients with moderate to severe acute pancreatitis showed a lower rate (although not statistically significant) of complications in patients treated with 3X200 and 3X500 pugIday octreotide, compared with controls and patients receiving a lower dose of octreotide. A further study showed a significant reduction in patient controlled analgesics in patients treated with octreotide compared with controls. Pain is the important clinical symptom of chronic pancreatitis, possibly resulting from an increased intraductal pressure during secretion. The effect on pain of the inhibition of pancreatic secretion by octreotide has been investigated in two studies. One showed no significant reduction in pain after treatment with octreotide for three days. In the other, in which octreotide was used for three weeks, significantly less pain and analgesic use was recorded during octreotide treatment than during placebo. The most common complication ofchronic pancreatitis is the formation of pseudocysts. There is some evidence that octreotide may be usefil in their treatnent.
Somatostatin in acute pancreatitis
Acute interstitial pancreatitis is a mild and self limiting disease that responds well to conservative treatment.1 2 Therefore, it is associated with low complication and death rates. Ten to 20% of all patients with acute pancreatitis, however, develop peripancreatic and intrapancreatic necrosis. 3 The release of toxic and vasoactive substances may lead to major systemic and metabolic complications followed by organ failure and death."
At present, there is no specific and effective treatment available for acute pancreatitis. Therefore, treatment, especially of acute necrotising pancreatitis, consists of symptomatic treatment in an intensive care unit.1-8
The lack of specific treatment for acute pancreatitis is possibly one explanation why the death rates associated with severe acute necrotising pancreatitis are still high (10-30/o In animal studiesl' 11 using various pancreatitis models it has been shown that basal and stimulated pancreatic secretion is reduced in rats or mice with acute pancreatitis. Data on secretion in the human pancreas during the inflammatory phase of acute pancreatitis are scarce.
Regan et al'2 found increased pancreatic secretion of lipase and trypsin in two of three patients with acute pancreatitis who were seen in a clinical study on cimetidine and glucagon. Recently, we have reported that in six patients with mild or moderate acute pancreatitis, basal pancreatic secretion is similar to that in healthy subjects. 13 After an attack of acute pancreatitis, the secretory capacity of the pancreas becomes temporarily insufficient. The degree of pancreatic insufficiency depends on the severity of the inflammatory process in the pancreas.'1 '7 It is, however, not known at what point during the course of acute pancreatitis this insufficiency occurs, and further studies are necessary to answer this important question.
In cases of acute pancreatitis after pancreatic transplantation, which might possibly be considered a model to study acute pancreatitis Biichler, Binder, Friess in humans, exocrine pancreatic function has been shown to be dependent on the degree of severity of the pancreatic inflammation.18 The more severe the transplantation pancreatitis, the less pancreatic secretion was present.
It is known that normal or food induced endogenous stimulation of the pancreas during inflammation worsens the course of acute pancreatitis and is absolutely contraindicated. In the basic treatment of the disease, endogenous stimulation is prevented by oral alimentary abstinence and continuous nasogastric suction.7 It is still controversial, however, whether basic treatment of acute pancreatitis should include the administration of secretion inhibiting substances. In a number of animal studies19-23 the effect of somatostatin and octreotide on the course of acute pancreatitis was investigated. There were some differences in both the experimental set up and the results of these studies. As some of the investigators gave secretion inhibiting substances before induction of acute pancreatitis and as secretion patterns during acute pancreatitis seem to differ between animals and humans, the results should not be transferred to the human situation. 24 The pathophysiological prerequisites for the use of secretion inhibiting substances for acute pancreatitis have not been fully clarified. Animal data showed a considerable reduction of secretion of the inflamed pancreas.'0 11 The studies of human pancreatitis showed normal secretion function,13 whereas in transplantation pancreatitis, the amount of secretion depends on the degree of severity of the pancreatitis.18 There have been too few human studies, however, to permit any conclusions to be drawn. This controversial situation surely warrants putting the treatment principle 'inhibition of pancreatic secretion' to the clinical test. The first clinical study in which somatostatin was used for acute pancreatitis was published by Limberg and Kommerell in 1980.30 In a study of 14 patients they found 'an impressive clinical improvement in all patients'. This promising finding was tested in several controlled clinical studies.31-34 Although the patients treated with somatostatin showed a lower complication rate, death rate, and better biochemical parameters, statistical significance could not be established. In a meta analysis35 Carballo analysed the statistical quality of six randomised studies in which somatostatin was given for acute pancreatitis (Table I) . In these individual studies no statistically significant effect on mortality could be proved. The meta analysis showed that, taking these six studies together, somatostatin significantly reduces the mortality associated with acute pancreatitis (p<0-01, Table I ). Further prospective studies with somatostatin or its analogues are necessary,36 using sufficient numbers of patients.
OCTREOTIDE IN ACUTE PANCREATITIS
We evaluated the effect of octreotide on the course of severe acute pancreatitis in an open prospective phase I/II study. Only patients with moderate to severe pancreatitis were included in the study. After randomisation eight patients in each group were treated either with 3X 100 ,ug/day, 3X200 p,g/day or 3X500 ,ug/day octreotide subcutaneously for 10 days. Complications were assessed according to a standard scoring system29 (Table II) on admission to hospital and in the follow up within 30 days.
A positive difference between the admission score and the follow up score was regarded as a positive treatment effect. A total of 24 patients (10 male, 14 In a further controlled study39 19 patients with acute pancreatitis were either treated with octreotide (250 jig subcutaneously, followed by 0-5 jig/kg/hour) or acted as controls. A significant reduction of the patient controlled consumption of analgesics was seen in octreotide treated patients compared with the controls (p<005). Unfortunately, only patients with mild pancreatitis were admitted to this study, so that no conclusion can be made as to the differences in mortality between the octreotide and control groups. The possible analgesic effect of somatostatin in human acute pancreatitis has been confirmed in an Italian multicentre study.32
PERSPECTIVES
The mechanism by which somatostatin and its analogue octreotide act on acute pancreatitis has been considered to be inhibition of exocrine pancreatic function. Another explanation stems from the notion of a 'cytoprotective' effect of these substances.40-42 Schwedes et al21 induced acute pancreatitis in dogs by injecting bile into the ductal system and found considerably less macroscopic and histological damage to the pancreas in animals treated with somatostatin than in the control group. The inhibitory effect of somatostatin on pancreatic secretion could not, however, be solely responsible for these differences. The authors assumed that somatostatin had a further direct protective effect on the pancreatic acinar cells.
In a double blind randomised clinical study, Choi et a133 saw a 'beneficial local effect' of somatostatin and that 'local inflammation was suppressed by somatostatin treatment'. Jenkins et al43 studied the effect of somatostatin and octreotide on the reticuloendothelial system in rats with acute pancreatitis and recorded increased hepatic and splenic reticuloendothelial system activity. Furthermore, octreotide was shown to significantly reduce endotoxin concentrations in the serum. In patients with cirrhosis of the liver and portal hypertension octreotide increased the phagocyte activity of the monocytes. The new approach to the treatment of complications associated with chronic pancreatitis by somatostatin analogues is encouraging. Octreotide, a potent inhibitor of exocrine basal and stimulated pancreatic secretion, has been successfully used to prevent postoperative complications after pancreatic surgery57 and to treat pancreatic fistulae.58 The treatment of pancreatic pseudocysts and ascites with octreotide is the logical extension of this management concept.
Further studies are required, however, to find out if octreotide or the combination of percutaneous catheter drainage and octreotide treatment can reduce the rate of surgery necessary for symptomatic pseudocysts.
It has been suggested that the damaged pancreas reacts less effectively to the inhibitory effect of somatostatin on pancreatic exocrine secretion.59 The positive results,52-58 however, of octreotide in patients with chronic pancreatitis show that secretion inhibiting substances may be a new treatment concept in such patients.
